One of the market's hottest stocks on Thursday was Novogen (NVGN), a speculative biotech. I bought shares back in February and laid out my investment thesis for subscribers why I thought shares could double in 2015. Part of that thesis has proven true, but I still think shares are undervalued. Subscribers can look back at that original post and see what key dates could impact shares and where they could be headed based on the company's timeline. 

The results from Novogen continue to strengthen the Stocks Under $20 portfolio and also showing what kind of an impact a small allocation to the biotech/medical field can have. 

There are currently 8 holdings in these two sectors in the Stocks Under $20 portfolio. Here is a look at the returns:

+468%

+101%

+96%

+28%

-9%

-18%

-25%

-44%

This translates to an average gain of 74.6%. If the big winner (+468%) is stripped out, the average gain is still +16%. 

Thank you for following along with the Stocks Under $20 portfolio. It is my goal to get more content available to both subscribers and free followers. If you haven't subscribed, remember that these people get my picks first and also get real time alerts when portfolio moves are made. Each subscription comes with a 30 day money back guarantee, so feel free to subscribe, read some back articles and decide if the strategy is right for you.

Happy investing,

Chris